Pharmacia & Upjohn Detrol
Selectivity claims in a Detrol (tolterodine) brochure suggesting that the drug is selective for overactive bladder versus salivary glands have not been demonstrated in humans, FDA says in an April 13 letter to P&U. The agency also objects to bar graphs in the brochure indicating a 50% decrease in urge incontinence episodes for Detrol patients versus 32% for placebo. The presentation "omits facts material in light of representations concerning the effectiveness of Detrol," FDA says. "Specifically, the difference between the reduction in urge urinary incontinence episodes with Detrol from baseline (-1.2 episodes per 24 hours) and placebo (-0.8 episodes per 24 hours) is not significant"
You may also be interested in...
The tolerability profile of Pharmacia's overactive bladder treatment Detrol is not sufficient evidence to support patient compliance claims, FDA's Division of Drug Marketing, Advertising & Communications indicated in a Dec. 7 letter to the company.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011